RA
KURA icon

Royce & Associates’s Kura Oncology KURA Stock Holding History

Royce & Associates’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.69M Buy
+609,985
New +$5.76M 0.05% 456

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Royce & Associates's KURA Position: Q2 2026 in Review

Royce & Associates opened a new position in Kura Oncology (KURA) in Q2 2026: 609,985 shares worth $6.69M. The stake represents 0.05% of the portfolio and ranks #456 among its holdings.

220 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Royce & Associates held 609,985 shares of Kura Oncology worth $6.69M as of Q2 2026.
  • Kura Oncology was a new Royce & Associates position in Q2 2026.
  • Kura Oncology made up 0.05% of Royce & Associates's portfolio in Q2 2026, its #456 holding.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.